Outcome of Board Meeting held on Held On Friday, 29th May 2026.
BROOKS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Brooks Laboratories Ltd reported audited FY2026 standalone revenue of Rs. 8,573.84 lakhs (up 3.85% from Rs. 8,255.68 lakhs in FY25) and standalone PAT of Rs. 580.50 lakhs (up 90% from Rs. 305.22 lakhs), driven by improved operations and a significant turnaround in the jointly controlled entity Brooks Steriscience Ltd which contributed Rs. 1,877.85 lakhs to consolidated PAT of Rs. 2,458.35 lakhs versus a loss of Rs. 996.70 lakhs in FY25. Statutory auditors issued an unmodified (clean) opinion. The company disclosed that its proposed diversification plan (object clause alteration) was rejected by ROC, so it continues focusing solely on pharmaceutical manufacturing and distribution. Mr. Prashant Rathi was appointed CEO in addition to his existing CFO role. Deferred tax assets remain unrecognized due to uncertainty over future taxable profits.
Strong operational turnaround with 90% PAT growth on standalone basis and return to profit at consolidated level. The failed diversification and dual CEO/CFO role may attract investor scrutiny. Clean audit opinion provides assurance on financial reporting quality.